The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl
Objective: To explore the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) with icosapent ethyl (IPE), we estimated (1) the number of ASCVD events and healthcare costs that could be prevented; a...
Saved in:
Main Authors: | Catherine G. Derington (Author), Adam P. Bress (Author), Jennifer S. Herrick (Author), Wenjun Fan (Author), Nathan D. Wong (Author), Katherine E. Andrade (Author), Jonathan Johnson (Author), Sephy Philip (Author), David Abrahamson (Author), Lixia Jiao (Author), Deepak L. Bhatt (Author), William S. Weintraub (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Icosapent ethyl for the treatment of severe hypertriglyceridemia
by: Fares H, et al.
Published: (2014) -
Reduction of Revascularizations in Patients with Hypertriglyceridemia with Icosapent Ethyl: Insights from REDUCE-IT REVASC
by: Benjamin E. Peterson, M.D, et al.
Published: (2020) -
Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
by: Lachaine J, et al.
Published: (2023) -
Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014
by: Wenjun Fan, et al.
Published: (2020) -
Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020
by: Joshua A. Jacobs, et al.
Published: (2024)